Wells Fargo
ESPR icon

Wells Fargo’s Esperion Therapeutics ESPR Stock Holding History

Wells Fargo’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,000
Closed -$109K – 6384
2018
Q1 		$109K Buy
+20,000
New +$1.47M ﹤0.01% 5267

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Wells Fargo's ESPR Position: Q2 2026 in Review

Wells Fargo increased its Esperion Therapeutics (ESPR) stake by 137% in Q2 2026, buying an estimated $355K and bringing the position to 219,777 shares worth $694K. The position accounts for ﹤0.01% of the portfolio, ranked #4374.

Wells Fargo first reported a position in ESPR in Q3 2013 and has held it in 52 quarters since. The position peaked at $17.6M in Q2 2018. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Wells Fargo held 219,777 shares of Esperion Therapeutics worth $694K as of Q2 2026.
  • Wells Fargo bought 126,897 Esperion Therapeutics shares in Q2 2026, an estimated $355K.
  • Esperion Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4374 holding.
  • Wells Fargo first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Wells Fargo's Esperion Therapeutics position peaked at $17.6M in Q2 2018.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.